Replies to post #183523 on NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

flipper44,

Why didn't her hypothetical trial end with no SOC only patients receiving treatment? That does not seem to fit a trial that has no chance of statistically significant endpoints. Everything must fit. Clinical observations vs trial parameters appear to be the difference. Trial parameters win the discussion when a trial is referrenced by a principal investigator. The trial is probably still waiting on final adjudication and Dr. Linda Liau would not comment on that. If an option is still available it's best not to write it off too soon.

Try to enjoy your time off chillaxing and if you can't stay away then focus on the big picture because it is almost done and you helped draw it for us. You have put in a ton of time here and we all appreciate it. Best wishes.

[beartrap12]

Flipper, none of Dr. Liau’s comments amounted to her being negative about the trial. They were simply facts which we already have, and many of her comments amounted to most immunotherapies.
I want to point out two things that are obvious in every video we watch of her and every scientific paper she writes.
1) Dr. Liau wants to find a cure, not just gain a few months or a few years for her patients. Unlike all of us, she knows the faces of her patients and has watched them suffer and fight for their lives. Their deaths undoubtedly follow her whether she won them time here on earth or not.
2) She’s a scientist and all scientists are raised on the scientific inquiry or method of handling trials. Ask any middle schooler or high schooler and if they’ve paid any attention in science class (and probably they haven’t) they’ll tell you that the scientific method requires them to ask such questions as, “How can I improve this trial?” and “Was there any bias in my trial? “ Also, “How could I improve my trial.” I taught science in the classsroom so I know these are standard questions. When scientists write up their trial reports, they are supposed to tell other scientists the weaknesses in their trial and how it could be improved in the future. I can tell you from having read many of Dr. Liau’s journal papers that she takes that section seriously and reports the weaknesses in her trial design. And she also tells her colleagues how to improve upon it. So, you can’t ask her to be a good politician and only present the rosy side of the picture when she has always been the blunt and honest scientist/doctor. I know some of her colleagues seem to have learned to gloss over their treatment failures and push their creations, but that’s not Dr. Liau. She seems consumed with the failings of her own treatment, which in her case in not necessarily a negative thing. As long as she doesn’t have a cure, she will work harder to turn a treatment that works for most, but in varying degrees, into hopefully someday a cure for all.